
DNLI
Healthcare · Biotechnology · $3.00B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 3, 2026 | After the close | -0.69 | -0.64 | +7.2% |
| Aug 6, 2026 | After the close | -0.72 | -0.68 | +5.6% |
| May 7, 2026 | After the close | -0.71 | -0.69 | +2.8% |
| Feb 26, 2026 | Time not confirmed | -0.75 | -0.73 | +2.7% |
| Nov 6, 2025 | After the close | -0.76 | -0.74 | +2.6% |
| Aug 11, 2025 | After the close | -0.74 | -0.72 | +2.7% |
| May 6, 2025 | After the close | -0.70 | -0.78 | -11.4% |
| Feb 25, 2025 | Before the open | -0.85 | -0.67 | +20.8% |
| Nov 6, 2024 | After the close | -0.63 | -0.63 | 0.0% |
| Aug 1, 2024 | Before the open | -0.69 | -0.59 | +14.5% |
| May 7, 2024 | After the close | -0.66 | -0.78 | -18.2% |
| Feb 27, 2024 | Before the open | -0.80 | -0.86 | -7.5% |
| Nov 7, 2023 | After the close | -0.79 | -0.72 |
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA…
| +8.9% |
| Aug 8, 2023 | After the close | -0.63 | 1.30 | +306.3% |
| May 8, 2023 | After the close | -0.70 | -0.80 | -14.3% |
| Feb 27, 2023 | After the close | -0.79 | -0.75 | +5.1% |
| Nov 3, 2022 | After the close | -0.79 | -0.84 | -6.3% |
| Aug 8, 2022 | After the close | -0.55 | -0.48 | +12.7% |
| May 5, 2022 | After the close | -0.45 | -0.53 | -17.8% |
| Feb 28, 2022 | After the close | -0.41 | -0.62 | -51.2% |
| Nov 4, 2021 | After the close | -0.38 | -0.69 | -81.6% |
| Aug 4, 2021 | After the close | -0.36 | -0.50 | -38.9% |
| May 3, 2021 | Before the open | -0.34 | -0.58 | -70.6% |
| Feb 25, 2021 | After the close | -0.60 | 1.91 | +418.3% |
| Nov 5, 2020 | After the close | 2.20 | -0.54 | -124.5% |
| Aug 7, 2020 | After the close | -0.61 | -0.56 | +8.2% |
| May 7, 2020 | After the close | -0.57 | -0.55 | +3.5% |
| Feb 27, 2020 | After the close | -0.58 | -0.56 | +3.4% |
| Nov 6, 2019 | After the close | -0.55 | -0.48 | +12.7% |
| Aug 6, 2019 | After the close | -0.46 | -0.61 | -32.6% |
| May 8, 2019 | After the close | -0.44 | -0.41 | +6.8% |
| Mar 12, 2019 | Before the open | -0.11 | 0.79 | +818.2% |
| Nov 8, 2018 | After the close | -0.29 | -0.38 | -31.0% |
| Aug 9, 2018 | After the close | -0.22 | -0.59 | -168.2% |
| May 11, 2018 | Before the open | 0.30 | -0.26 | -186.7% |
| Mar 19, 2018 | Before the open | -0.20 | -0.74 | -270.0% |